Welcome to Home page of CancerHLA-I
Advancements in cancer immunotherapy such as immune checkpoint inhibitors, adoptive T cell therapy have exhibited significant outcomes in treating various types of cancers. These therapies are entirely based on the T cells, which identify tumor-associated peptides presented by human leukocytes antigens (HLA) on the infected cell surface. Class-I HLA alleles interact with the T cell receptors to activate T cells which further induce several immune responses to knock off the tumor cells from our system. Recently, scientists majorly focused on HLA-dependent therapies, including CD8+ T cell therapy, tumor-infiltrating lymphocytes (TILs) therapy, and TCR-engineered T cells (TCR-Ts) therapy to treat cancer patients.
Dhall A., Patiyal S., Kaur H. and Raghava G. P. S. (2023) Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines. Computers in Biology and Medicine. doi.org/10.1016/j.compbiomed.2023.107594
Webinterface of CancerHLA-I database
Plots of CancerHLA-I showing data types
UpSet plot
Correlation of Cytokines and chemokines